PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Anticancer Research0 citations

Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer

View Full Paper
NWNoriko WadaYKYUKINORI KUROKAWATTTSUYOSHI TAKAHASHI

Key Points

  • This research aims to understand treatment patterns and factors affecting survival in patients with HER2-positive advanced gastric cancer.
  • Examined treatment patterns over time regarding anti-HER2 therapies.
  • Assessed the impact of adjusting cytotoxic partners on treatment continuation and patient outcomes.
  • Analyzed survival rates associated with sustained trastuzumab use.
  • Sustained anti-HER2 therapy led to significantly longer survival rates.
  • Adjusting cytotoxic partners helped patients maintain trastuzumab-based treatment longer.
  • Effective management of toxicity contributed to improved treatment outcomes.

Abstract

Sustained anti-HER2 therapy was strongly associated with longer survival. Adjusting the cytotoxic partner to manage toxicity may help patients continue trastuzumab-based treatment and achieve better outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wada et al. (2026) studied this question.

synapsesocial.com/papers/6980ff49c1c9540dea81222fhttps://doi.org/10.21873/anticanres.18001
Ask AI
Helpful
Bookmark
Share
View Full Paper